ARCA BIOPHARMA INC (ABIO)

US00211Y5069 - Common Stock

1.76  +0.01 (+0.57%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ARCA BIOPHARMA INC

NASDAQ:ABIO (3/28/2024, 8:00:00 PM)

1.76

+0.01 (+0.57%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap25.52M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ABIO Daily chart

Company Profile

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of targeted therapies for cardiovascular diseases. The company is headquartered in Broomfield, Colorado and currently employs 5 full-time employees. The company went IPO on 2000-07-21. The firm's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF), in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that the Company is developing for the treatment of AF in patients with heart failure. The firm's Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. The rNAPc2 is in a phase IIb clinical trial as a potential treatment for patients hospitalized with COVID-19.

Company Info

ARCA BIOPHARMA INC

Suite 430, 8001 Arista Place

Broomfield COLORADO 80021

P: 17209402200

CEO: Michael R. Bristow

Employees: 5

Website: https://arcabio.com/

ABIO News

News Image2 months ago - ARCA biopharma, Inc.ARCA biopharma Announces 2023 Financial Results

ARCA biopharma Announces 2023 Financial Results...

News Image5 months ago - ARCA biopharma, Inc.ARCA biopharma Announces Third Quarter 2023 Financial Results

ARCA biopharma Announces Third Quarter 2023 Financial Results...

News Image8 months ago - ARCA biopharma, Inc.ARCA biopharma Announces Second Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options ...

News Imagea year ago - ARCA biopharma, Inc.ARCA biopharma Announces First Quarter 2023 Financial Results

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options...

News Imagea year ago - ARCA biopharma, Inc.ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options...

News Imagea year ago - ARCA biopharma, Inc.James Flynn Joins ARCA biopharma Board of Directors

WESTMINSTER, Colo., Dec. 19, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO) today announced that James Flynn has joined its Board of...

ABIO Twits

Here you can normally see the latest stock twits on ABIO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example